News

Announced M&A in EMEA rose 16% in the six months to June but FIG dealmaking surged 48% to $85bn. That made it the busiest first half since 2007, according to Dealogic. The deals are varied, from ...
Banco do Brasil continues to invest in its digital transformation, with the migration to Windows 11 Enterprise serving as the foundation for a broader shift focused on security, process automation, ...
Novo Nordisk, arguing that Hims & Hers is abusing compounding as a loophole to bypass its patent, terminated the sales agreement.
Novo Nordisk NOVO.B -0.28% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.
Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.
(Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Under the deal, cash-paying patients can access a ...
Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with ...
With all doses of FDA-approved Wegovy ® fully available nationwide, it is illegal under U.S. compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptions. Novo Nordisk continues ...
June 26 (Reuters) - Novo Nordisk (NOVOb.CO) said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.
Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their prescription filled through CenterWell Pharmacy, now associated with Novo ...
The breakup between Novo Nordisk and Hims & Hers remains acrimonious. Recent remarks highlight the competition facing Novo Nordisk's Wegovy. Shares in Denmark's pharmaceutical giant Novo Nordisk ...